The concomitant determination of different serum tumor markers in epithelial ovarian cancer: Relevance for monitoring the response to chemotherapy and follow-up of patients
- 18 February 1992
- journal article
- Published by Elsevier in Gynecologic Oncology
- Vol. 44 (2) , 155-160
- https://doi.org/10.1016/0090-8258(92)90031-d
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Tumor markers in gynecologic oncologyGynecologic Oncology, 1990
- Use of CA 125 to monitor patients with ovarian epithelial carcinomasGynecologic Oncology, 1989
- The CA 125 tumour-associated antigen: a review of the literatureHuman Reproduction, 1989
- The role of cancer antigen 125 (CA 125) in the management of ovarian epithelial carcinomasGynecologic Oncology, 1988
- Correlation of CA125 and CA19-9 serum levels with clinical course and second-look findings in patients with ovarian carcinomaGynecologic Oncology, 1987
- Serum CA 125 levels in epithelial ovarian cancer: relation with findings at second‐look operations and their role in the detection of tumour recurrenceBJOG: An International Journal of Obstetrics and Gynaecology, 1987
- CA 125 surveillance and second-look laparotomy in ovarian carcinomaAmerican Journal of Obstetrics and Gynecology, 1986
- Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumour markerBritish Journal of Cancer, 1984
- Monitoring human ovarian carcinoma with a combination of CA 125, CA 19-9, and carcinoembryonic antigenAmerican Journal of Obstetrics and Gynecology, 1984
- A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian CancerNew England Journal of Medicine, 1983